We can’t show the full text here under this license. Use the link below to read it at the source.
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease
Sodium-glucose cotransporter-2 inhibitors linked to slower kidney disease progression than dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in UK clinics
AI simplified
Abstract
SGLT2 inhibitor initiation was associated with 7.48 events per 1000 patient-years for composite kidney endpoints compared to 11.77 for DPP-4 inhibitors.
- SGLT2 inhibitors were linked to a 36% reduction in the risk of the primary composite endpoint.
- All-cause mortality risk was reduced by 26% with SGLT2 inhibitors compared to DPP-4 inhibitors.
- The risk of was decreased by 63% with SGLT2 inhibitor use.
- SGLT2 inhibitors were associated with a 67% lower rate of sustained low estimated glomerular filtration rate.
- Diagnoses of end-stage kidney disease in primary care were significantly lower with SGLT2 inhibitors.
AI simplified
Key numbers
7.48 events per 1000 patient-years
Reduction in Composite Events
SGLT2 inhibitor initiation
0.64
Hazard Ratio for Primary Composite Endpoint
Compared to DPP-4 inhibitors
0.74
All-Cause Mortality Hazard Ratio
Compared to DPP-4 inhibitors